Literature DB >> 14963467

Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats.

T J Bivalacqua1, M F Usta, H C Champion, S Leungwattanakij, P A Dabisch, D B McNamara, P J Kadowitz, W J G Hellstrom.   

Abstract

Erectile dysfunction associated with diabetes mellitus is caused in part by disordered endothelial smooth muscle relaxation, neuropathy, and a decrease in cavernosal nitric oxide synthase (NOS) activity. The purpose of this study was to determine whether a combination of sildenafil and adenoviral gene transfer of endothelial NOS (eNOS) could enhance the erectile response in diabetic rats. Five groups of animals were utilized: (1) age-matched control rats, (2) streptozotocin (STZ)-induced diabetic rats (60 mg/kg i.p.), (3) STZ-rats + sildenafil (2 mg/kg i.v.), (4) STZ-rats transfected with AdCMVbetagal or AdCMVeNOS, and (5) STZ-rats transfected with AdCMVeNOS +sildenafil (2 mg/kg i.v.). At 2 months after i.p. injection of STZ, groups 4 and 5 were transfected with the adenoviruses and 1-2 days after transfection, all animals underwent cavernosal nerve stimulation (CNS) to assess erectile function. Cyclic 3',5'-guanosine monophosphate (cGMP) levels were assessed in the cavernosal tissue. STZ-diabetic rats had a significant decrease in erectile function as determined by the peak intracavernosal pressure (ICP) and total ICP (area under the erectile curve; AUC) after CNS when compared to control rats. STZ-diabetic rats+AdCMVeNOS had a peak ICP and AUC, which were similar to control animals. STZ-diabetic rats administered sildenafil demonstrated a significant increase in peak ICP at the 5 and 7.5 V settings, while the AUC was significantly increased at all voltage (V) settings. The increase in both ICP and AUC of STZ-diabetic rats transfected with AdCMVeNOS at all V settings was greater than STZ-diabetic rats transfected with AdCMVbetagal. STZ-diabetic rats transfected with AdCMVeNOS and administered sildenafil had a significant increase in total ICP that was greater than eNOS gene therapy alone. Cavernosal cGMP levels were significantly decreased in STZ-diabetic rats, but were increased after transfection with AdCMVeNOS to values greater than control animals. In conclusion, overexpression of eNOS and cGMP in combination with sildenafil significantly increased both the peak ICP and total ICP to CNS in the STZ-diabetic rat, which was similar to the response observed in control rats. Moreover, the total erectile response was greater in STZ-diabetic rats receiving eNOS gene therapy plus sildenafil than STZ-rats receiving sildenafil or eNOS gene therapy alone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14963467     DOI: 10.1038/sj.ijir.3901054

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  14 in total

Review 1.  Mesenchymal stem cell-based gene therapy for erectile dysfunction.

Authors:  J H Kim; H J Lee; Y S Song
Journal:  Int J Impot Res       Date:  2016-02-18       Impact factor: 2.896

2.  Inactivation of phosphorylated endothelial nitric oxide synthase (Ser-1177) by O-GlcNAc in diabetes-associated erectile dysfunction.

Authors:  Biljana Musicki; Melissa F Kramer; Robyn E Becker; Arthur L Burnett
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-05       Impact factor: 11.205

Review 3.  Emerging and novel therapeutic approaches in the treatment of male erectile dysfunction.

Authors:  Eric Chung; Gerald B Brock
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

Review 4.  Erectile Dysfunction and Ischaemic Heart Disease.

Authors:  Abdalla Ibrahim; Mohamed Ali; Thomas J Kiernan; Austin G Stack
Journal:  Eur Cardiol       Date:  2018-12

Review 5.  Emerging gene and stem cell therapies for the treatment of erectile dysfunction.

Authors:  Ahmed Harraz; Alan W Shindel; Tom F Lue
Journal:  Nat Rev Urol       Date:  2010-02-16       Impact factor: 14.432

Review 6.  Advances in pharmacologic modulation of nitric oxide in hypertension.

Authors:  Yoshiko Mizuno; Robert F Jacob; R Preston Mason
Journal:  Curr Cardiol Rep       Date:  2010-11       Impact factor: 2.931

7.  Chronic oral administration of the arginase inhibitor 2(S)-amino-6-boronohexanoic acid (ABH) improves erectile function in aged rats.

Authors:  Robert Segal; Johanna L Hannan; Xiaopu Liu; Omer Kutlu; Arthur L Burnett; Hunter C Champion; Jae Hyung Kim; Jochen Steppan; Dan E Berkowitz; Trinity J Bivalacqua
Journal:  J Androl       Date:  2012-04-05

Review 8.  Gene therapy as future treatment of erectile dysfunction.

Authors:  Naoki Yoshimura; Ryuichi Kato; Michael B Chancellor; Joel B Nelson; Joseph C Glorioso
Journal:  Expert Opin Biol Ther       Date:  2010-09       Impact factor: 4.388

9.  Ca2+ -activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction.

Authors:  R González-Corrochano; Jm La Fuente; P Cuevas; A Fernández; Mx Chen; I Sáenz de Tejada; J Angulo
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

Review 10.  Gas what: NO is not the only answer to sexual function.

Authors:  G Yetik-Anacak; R Sorrentino; A E Linder; N Murat
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.